Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease
Authors:
- Federica SotgiaFSFederica Sotgia
- Scott E. WoodmanSWScott E. Woodman
- Gloria BonuccelliGBGloria Bonuccelli
- Franco CapozzaFCFranco Capozza
- Carlo MinettiCMCarlo Minetti
- Philipp E. SchererPSPhilipp E. Scherer
- Michael P. LisantiMLMichael P. Lisanti
- 1 November 2003
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 285 (5) , C1150-C1160
Abstract
Four different phenotypes have been associated with CAV3 mutations: limb girdle muscular dystrophy-1C (LGMD-1C), rippling muscle disease (RMD), and distal myopathy (DM), as well as idiopathic and familial hyperCKemia (HCK). Detailed molecular characterization of two caveolin-3 mutations (P104L and ΔTFT), associated with LGMD-1C, shows them to impart a dominant-negative effect on wild-type caveolin-3, rendering it dysfunctional through sequestration in the Golgi complex. Interestingly, substitution of glutamine for arginine at amino acid position 26 (R26Q) of caveolin-3 is associated not only with RMD but also with DM and HCK. However, the phenotypic behavior of the caveolin-3 R26Q mutation has never been evaluated in cultured cells. Thus we characterized the cellular and molecular properties of the R26Q mutant protein to better understand how this mutation can manifest as such distinct disease phenotypes. Here, we show that the caveolin-3 R26Q mutant is mostly retained at the level of the Golgi complex. The caveolin-3 R26Q mutant formed oligomers of a much larger size than wild-type caveolin-3 and was excluded from caveolae-enriched membranes. However, caveolin-3 R26Q did not behave in a dominant-negative fashion when coexpressed with wild-type caveolin-3. Thus the R26Q mutation behaves differently from other caveolin-3 mutations (P104L and ΔTFT) that have been previously characterized. These data provide a possible explanation for the scope of the various disease phenotypes associated with the caveolin-3 R26Q mutation. We propose a haploinsufficiency model in which reduced levels of wild-type caveolin-3, although not rendered dysfunctional due to the caveolin-3 R26Q mutant protein, are insufficient for normal muscle cell function.Keywords
This publication has 49 references indexed in Scilit:
- Mutational Analysis of the Properties of Caveolin-1Journal of Biological Chemistry, 1997
- Caveolae and caveolinsCurrent Opinion in Cell Biology, 1996
- Expression of Caveolin-3 in Skeletal, Cardiac, and Smooth Muscle CellsJournal of Biological Chemistry, 1996
- Identification, sequence, and expression of caveolin-2 defines a caveolin gene family.Proceedings of the National Academy of Sciences, 1996
- Molecular Cloning of Caveolin-3, a Novel Member of the Caveolin Gene Family Expressed Predominantly in MuscleJournal of Biological Chemistry, 1996
- Caveolin Isoforms Differ in Their N-terminal Protein Sequence and Subcellular Distribution. IDENTIFICATION AND EPITOPE MAPPING OF AN ISOFORM-SPECIFIC MONOCLONAL ANTIBODY PROBEJournal of Biological Chemistry, 1995
- Caveolin Is Palmitoylated on Multiple Cysteine ResiduesJournal of Biological Chemistry, 1995
- The sequence of human caveolin reveals identity with VIP21, a component of transport vesiclesFEBS Letters, 1992
- Caveolin, a protein component of caveolae membrane coatsCell, 1992
- THE FINE STRUCTURE OF THE GALL BLADDER EPITHELIUM OF THE MOUSEJournal of Cell Biology, 1955